hgd40
Chronic Inflammatory Diseases (e.g., Asthma, Atopic Dermatitis, Ulcerative Colitis, COPD)
Phase 2Active
Key Facts
Indication
Chronic Inflammatory Diseases (e.g., Asthma, Atopic Dermatitis, Ulcerative Colitis, COPD)
Phase
Phase 2
Status
Active
Company
About Sterna Biologicals & KG
Sterna Biologicals is a German biotech focused on disrupting the treatment of type 2 chronic inflammatory diseases through its proprietary GATA-3 targeting platform. The company's lead asset, hgd40, has completed multiple Phase IIa clinical trials in topical formulations for conditions like asthma, atopic dermatitis, ulcerative colitis, and COPD. Sterna operates as a private, clinical-stage company and is actively seeking partnerships to advance its innovative DNAzyme technology. Its approach aims to address the significant unmet need for safer and more efficacious anti-inflammatory therapies beyond corticosteroids and biologics.
View full company profile